Menten AI Participates in BioEurope Spring 2024

March 20, 2024

BioEurope 2024

Next Generation: Menten AI, Inc.

At the recent Spring BioEurope conference in Barcelona, Menten AI's CEO, Dr. Hans Melo, took the stage to share insights into the cutting-edge applications of artificial intelligence (AI) in peptide therapeutics. Dr. Melo's presentation catered to a diverse audience, offering a high-level overview of how Menten AI harnesses its proprietary physics-based generative AI methods to streamline the development of cyclic peptide therapeutics.

Dr. Melo highlighted the notable reduction in design timelines achieved through Menten AI's platform, while maintaining precision and accuracy. He elaborated on the company's ongoing advancements, which include the integration of machine learning (ML) and molecular dynamics (MD) techniques, our processes for target assessment, our multi-parameter optimization methods and case studies, as well as our innovative strategies to tackle challenges such as permeability and oral bioavailability.

Importantly, Dr. Melo emphasized Menten AI's collaborative approach in supporting partners' drug discovery efforts. By tailoring peptides to meet the specific needs of each project, Menten AI ensures a customized solution for every partner.

You can view the full talk on our YouTube channel or below:

For further information on how our platform can be tailored to your requirements, please reach out to us at or our LinkedIn Page.

BioEurope Spring 2024

BIO-Europe Spring 2024 recently took place in Barcelona, Spain, attracting over 2,000 companies from 59 countries. The event facilitated more than 19,000 one-to-one partnering meetings, offering attendees a platform for networking and collaboration. Participants had the opportunity to engage in various activities, such as fireside chats, expert panels, and company presentations, while also scheduling partnering meetings as part of their agenda.

For additional information, please visit: